96 results
Page 2 of 5
424B5
fit jgra3e7
17 Nov 23
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
jqvvmtx
13 Nov 23
Other Events
6:07am
8-K
EX-99.1
8sy0ah904lstbmy mfl2
7 Nov 23
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
8:05am
8-K
EX-99.1
4kah nctn1zaos8v
30 Oct 23
Other Events
5:24pm
8-K
EX-10.1
dmo8ip79ao
1 Sep 23
Entry into a Material Definitive Agreement
4:45pm
424B5
8qi rhazbvztqy
1 Sep 23
Prospectus supplement for primary offering
4:30pm
S-3
a29nbhp8 lzp3
14 Aug 23
Shelf registration
6:05pm
8-K
EX-99.1
b3we5 rwz
8 Aug 23
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
8:15am
FWP
ssduonihisgm0n 1m
11 Jul 23
Free writing prospectus
12:42pm
8-K
EX-99.1
q81og88w8ka3rkvqlyaw
11 Jul 23
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
10:26am
8-K
EX-99.1
5x0ed0
10 Jul 23
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
4:41pm
8-K
EX-99.1
b40ej8eagjiwvyi7ci9
20 Jun 23
Regulation FD Disclosure
9:06am
FWP
twmp2r9 s7k6
9 Jun 23
Free writing prospectus
6:47am
DRS
4xr2n0xp
1 Jun 23
Draft registration statement
12:00am
8-K
EX-99.1
t61 m3kq2x1tir
8 May 23
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
8:15am